These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 30306365)

  • 21. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-viral delivery of genome-editing nucleases for gene therapy.
    Wang M; Glass ZA; Xu Q
    Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
    Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
    Verma R; Sahu R; Singh DD; Egbo TE
    Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.
    Aquino-Jarquin G
    Mol Genet Metab; 2021; 134(1-2):77-86. PubMed ID: 34391646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
    Cai W; Luo T; Mao L; Wang M
    Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy.
    Wang L; Zheng W; Liu S; Li B; Jiang X
    Chembiochem; 2019 Mar; 20(5):634-643. PubMed ID: 30393919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets.
    Taghdiri M; Mussolino C
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
    Xu Y; Liu R; Dai Z
    Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
    Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J; Shah RR; Shah A; Ling D; Growe J; Pink M; Rohde E; Wood KM; Salomon WE; Harrington WF; Dombrowski C; Strapps WR; Chang Y; Morrissey DV
    Cell Rep; 2018 Feb; 22(9):2227-2235. PubMed ID: 29490262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications.
    Masarwy R; Stotsky-Oterin L; Elisha A; Hazan-Halevy I; Peer D
    Adv Drug Deliv Rev; 2024 Aug; 211():115359. PubMed ID: 38857763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Guanidinobenzol-Rich Polymer Overcoming Cascade Delivery Barriers for CRISPR-Cas9 Genome Editing.
    Liang S; Ma N; Li X; Yun K; Meng QF; Ma K; Yue L; Rao L; Chen X; Wang Z
    Nano Lett; 2024 Jun; 24(23):6872-6880. PubMed ID: 38683656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Latest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system.
    Yu M; Liu X; Cheng H; Kuang L; Zhang S; Yan X
    Methods; 2021 Oct; 194():48-55. PubMed ID: 34107351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
    Liu C; Zhang L; Liu H; Cheng K
    J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Application of nanoparticles in CRISPR/Cas9-based gene therapy].
    Ma Y; Deng L; Li S
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2087-2104. PubMed ID: 35786464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.
    Singh D
    AAPS PharmSciTech; 2024 Jun; 25(5):129. PubMed ID: 38844700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.
    Wang D; Chen L; Li C; Long Q; Yang Q; Huang A; Tang H
    J Nanobiotechnology; 2022 Jan; 20(1):27. PubMed ID: 34991617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.